Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
100.277,87
-0,39%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Indaptus Therapeutics Inc (INDP) Indaptus Therapeutics Inc (INDP) Notizie

INDP

Indaptus Therapeutics (INDP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INDP
DataOraFonteTitoloSimboloCompagnia
31/01/202522:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
22/01/202523:01Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:INDPIndaptus Therapeutics Inc
13/01/202514:00GlobeNewswire Inc.Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq RulesNASDAQ:INDPIndaptus Therapeutics Inc
08/01/202514:00GlobeNewswire Inc.Indaptus Therapeutics Provides Year-End Review and Outlook for 2025NASDAQ:INDPIndaptus Therapeutics Inc
02/01/202506:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:INDPIndaptus Therapeutics Inc
23/12/202422:52Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:INDPIndaptus Therapeutics Inc
22/11/202422:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:INDPIndaptus Therapeutics Inc
22/11/202414:36GlobeNewswire Inc.Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:INDPIndaptus Therapeutics Inc
12/11/202414:00GlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
11/11/202414:00GlobeNewswire Inc.Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in ImmunologyNASDAQ:INDPIndaptus Therapeutics Inc
07/11/202414:00GlobeNewswire Inc.Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
23/10/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present at Two Upcoming Investor ConferencesNASDAQ:INDPIndaptus Therapeutics Inc
22/10/202414:00GlobeNewswire Inc.Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment CombinationsNASDAQ:INDPIndaptus Therapeutics Inc
15/10/202414:00GlobeNewswire Inc.Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety DataNASDAQ:INDPIndaptus Therapeutics Inc
10/10/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
10/10/202414:00GlobeNewswire Inc.Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer ImmunotherapyNASDAQ:INDPIndaptus Therapeutics Inc
08/10/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitNASDAQ:INDPIndaptus Therapeutics Inc
04/10/202423:21Edgar (US Regulatory)Form D/A - Notice of Exempt Offering of Securities: [Amend]NASDAQ:INDPIndaptus Therapeutics Inc
05/09/202414:30GlobeNewswire Inc.Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different DosesNASDAQ:INDPIndaptus Therapeutics Inc
03/09/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
12/08/202414:16Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INDPIndaptus Therapeutics Inc
12/08/202414:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
12/08/202414:00GlobeNewswire Inc.Indaptus Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
07/08/202413:00GlobeNewswire Inc.Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private PlacementNASDAQ:INDPIndaptus Therapeutics Inc
11/06/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies SummitNASDAQ:INDPIndaptus Therapeutics Inc
04/06/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
03/06/202414:00GlobeNewswire Inc.Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
30/05/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
29/05/202414:00GlobeNewswire Inc.Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
22/05/202414:00GlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:INDP

La tua Cronologia

NASDAQ
BDSX
Biodesix
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci